U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H29FO5
Molecular Weight 392.4611
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXAMETHASONE

SMILES

[H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

InChIKey=UREBDLICKHMUKA-CXSFZGCWSA-N
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1

HIDE SMILES / InChI

Molecular Formula C22H29FO5
Molecular Weight 392.4611
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/pro/dexamethasone.html | http://www.wikidoc.org/index.php/Dexamethasone_(oral) | http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/040572s002lbl.pdf

Dexamethasone is an anti-inflammatory agent that is FDA approved for the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling and others. Dexamethasone is a glucocorticoid agonist. Unbound dexamethasone crosses cell membranes and binds with high affinity to specific cytoplasmic glucocorticoid receptors. Adverse reactions are: Glaucoma with optic nerve damage, visual acuity and field defects; cataract formation; secondary ocular infection following suppression of host response; and perforation of the globe may occur; muscle weakness; osteoporosis and others. Aminoglutethimide may diminish adrenal suppression by corticosteroids. Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

Launch Date

-2.37859193E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.37859193E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
MAXIDEX

Approved Use

For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens, and Streptococci, including Streptococcus pneumoniae.

Launch Date

-2.377728E11
Primary
Neofordex

Approved Use

Neofordex is indicated in adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products.

Launch Date

1.45799997E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
9.87 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
51.2 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.93 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
30%
DEXAMETHASONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
96 mg multiple, oral (total)
Dose: 96 mg
Route: oral
Route: multiple
Dose: 96 mg
Sources:
unhealthy, 63 years (range: 30–78 years)
n = 21
Health Status: unhealthy
Age Group: 63 years (range: 30–78 years)
Sex: M+F
Population Size: 21
Sources:
0.1 % 3 times / day multiple, ophthalmic
Dose: 0.1 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 0.1 %, 3 times / day
Sources:
unhealthy, 68.3 years (range: 51.0 - 83.0 years)
n = 77
Health Status: unhealthy
Age Group: 68.3 years (range: 51.0 - 83.0 years)
Sex: M+F
Population Size: 77
Sources:
Other AEs: Corneal erosion...
Other AEs:
Corneal erosion (10%)
Sources:
0.6 mg/kg single, oral
Dose: 0.6 mg/kg
Route: oral
Route: single
Dose: 0.6 mg/kg
Sources:
unhealthy, children
n = 6
Health Status: unhealthy
Condition: Migraine
Age Group: children
Population Size: 6
Sources:
Other AEs: Constipation...
Other AEs:
Constipation (below serious, 1 patient)
Sources:
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Other AEs: Drowsiness, Dizziness...
Other AEs:
Drowsiness (below serious, 19 patients)
Dizziness (below serious, 3 patients)
Adverse drug reaction NOS (below serious, 10 patients)
Sources:
12 mg 1 times / day multiple, intravenous
Dose: 12 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Other AEs: Wound dehiscence...
Other AEs:
Wound dehiscence (below serious, 1 patient)
Sources:
20 mg single, intravenous
Dose: 20 mg
Route: intravenous
Route: single
Dose: 20 mg
Sources:
unhealthy
Health Status: unhealthy
Sources:
24 mg 1 times / day multiple, intravenous
Dose: 24 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Other AEs: Dizziness...
Other AEs:
Dizziness (below serious, 1 patient)
Sources:
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Other AEs: Constipation, Dyspepsia...
Other AEs:
Constipation (below serious, 47 patients)
Dyspepsia (below serious, 12 patients)
Vomiting (below serious, 9 patients)
Fatigue (below serious, 58 patients)
Cholesterol high (below serious, 8 patients)
Anorexia (below serious, 15 patients)
Anxiety (below serious, 11 patient)
Insomnia (below serious, 26 patients)
Cough (below serious, 9 patients)
Dyspnea (below serious, 20 patients)
Sources:
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Other AEs: Incision site bleeding, Body temperature decrease...
Other AEs:
Incision site bleeding (below serious, 1 patient)
Body temperature decrease (below serious, 2 patients)
Shivering (below serious, 1 patient)
Tachycardia (below serious, 1 patient)
Transfusion (below serious, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Corneal erosion 10%
0.1 % 3 times / day multiple, ophthalmic
Dose: 0.1 %, 3 times / day
Route: ophthalmic
Route: multiple
Dose: 0.1 %, 3 times / day
Sources:
unhealthy, 68.3 years (range: 51.0 - 83.0 years)
n = 77
Health Status: unhealthy
Age Group: 68.3 years (range: 51.0 - 83.0 years)
Sex: M+F
Population Size: 77
Sources:
Constipation below serious, 1 patient
0.6 mg/kg single, oral
Dose: 0.6 mg/kg
Route: oral
Route: single
Dose: 0.6 mg/kg
Sources:
unhealthy, children
n = 6
Health Status: unhealthy
Condition: Migraine
Age Group: children
Population Size: 6
Sources:
Adverse drug reaction NOS below serious, 10 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Drowsiness below serious, 19 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Dizziness below serious, 3 patients
10 mg single, intravenous
Dose: 10 mg
Route: intravenous
Route: single
Dose: 10 mg
Sources:
unhealthy
n = 106
Health Status: unhealthy
Condition: Migraine
Population Size: 106
Sources:
Wound dehiscence below serious, 1 patient
12 mg 1 times / day multiple, intravenous
Dose: 12 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Dizziness below serious, 1 patient
24 mg 1 times / day multiple, intravenous
Dose: 24 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
unhealthy
n = 10
Health Status: unhealthy
Condition: Knee Arthroplasty
Population Size: 10
Sources:
Anxiety below serious, 11 patient
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Dyspepsia below serious, 12 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Anorexia below serious, 15 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Dyspnea below serious, 20 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Insomnia below serious, 26 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Constipation below serious, 47 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Fatigue below serious, 58 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Cholesterol high below serious, 8 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Cough below serious, 9 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Vomiting below serious, 9 patients
8 mg 1 times / day multiple, oral
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
unhealthy
n = 147
Health Status: unhealthy
Condition: Radiation-Induced Pain Flare
Population Size: 147
Sources:
Incision site bleeding below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Shivering below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Tachycardia below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Transfusion below serious, 1 patient
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Body temperature decrease below serious, 2 patients
8 mg single, intravenous
Dose: 8 mg
Route: intravenous
Route: single
Dose: 8 mg
Sources:
pregnant
n = 55
Health Status: pregnant
Sex: F
Population Size: 55
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: These data demonstrate that dexamethasone at doses used clinically increased CYP3A4 activity with extensive intersubject variability and that the extent of CYP3A4 induction was, in part, predicted by the baseline activity of CYP3A4 in both healthy volunteers and human hepatocyte cultures.
Page: -
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Regulation of RANTES and ICAM-1 expression in murine mesangial cells.
1997 Apr
Effect of antenatal glucocorticoid administration on insulin-like growth factor I and II levels in hypoplastic lung in nitrofen-induced congenital diaphragmatic hernia in rats.
1999
Glucocorticoids inhibit proliferation and adhesion of the IL-3-dependent mast cell line, MC/9, to NIH/3T3 fibroblasts, with an accompanying decrease in IL-3 receptor expression.
1999 Apr
Selective cyclo-oxygenase-2 inhibitors aggravate ischaemia-reperfusion injury in the rat stomach.
1999 Dec
Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors.
1999 Dec 24
Dexamethasone induced alterations in the levels of proteases involved in blood pressure homeostasis and blood coagulation in rats.
1999 Jul
[Iatrogenic Cushing syndrome and mutatio tarda caused by dexamethasone containing nose drops].
1999 Jul
Effects of inhaled beclomethasone compared to systemic dexamethasone on lung inflammation in preterm infants at risk of chronic lung disease.
1999 Jun
Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin-induced small intestinal lesions in rats.
1999 Mar
Effects of theophylline, dexamethasone and salbutamol on cytokine gene expression in human peripheral blood CD4+ T-cells.
1999 Nov
Dexamethasone therapy increases infection in very low birth weight infants.
1999 Nov
Dexamethasone enhances ras-recision gene expression in cultured murine fetal lungs: role in development.
2000 Aug
Dexamethasone suppresses tumor necrosis factor-alpha-induced apoptosis in osteoblasts: possible role for ceramide.
2000 Aug
Effect of endogenous and exogenous prostaglandin E(2) on interleukin-1 beta-induced cyclooxygenase-2 expression in human airway smooth-muscle cells.
2000 Dec
All-trans-retinoic acid-induced myositis: a description of two patients.
2000 Feb
Dexamethasone blocks sepsis-induced protection of the heart from ischemia reperfusion injury.
2000 Jan
Acrylamide-regulated neurofilament expression in rat pheochromocytoma cells.
2000 Jan 10
Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review.
2000 Jul 29
Down-regulation of thyroid transcription factor-1 gene expression in fetal lung hypoplasia is restored by glucocorticoids.
2000 Jun
Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding.
2000 Jun 23
beta(3)-adrenoceptor regulation and relaxation responses in mouse ileum.
2000 Mar
Ticlopidine-induced aplastic anemia: development of chromosomal abnormalities and response to immunosuppressive therapy.
2000 Mar
Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone.
2000 Mar 1
Effects of selected herbicides on cytokine production in vitro.
2000 May 19
Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis.
2000 Nov 10
Endotoxin augments cerebral hyperemic response to halothane by inducing nitric oxide synthase and cyclooxygenase.
2000 Oct
Involvement of tyrosine hydroxylase up regulation in dexamethasone-induced hypertension of rats.
2000 Sep 8
A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide.
2001 Feb
Molecular and pharmacological evidence for modulation of kinin B(1) receptor expression by endogenous glucocorticoids hormones in rats.
2001 Jan
Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network.
2001 Jan 11
Triptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAs.
2012 Jun
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.
2012 Jun
Patents

Sample Use Guides

The dose and administration frequency varies with the therapeutic protocol and the associated treatment(s). The usual posology of NEOFORDEX® is 40 mg once per day of administration.
Route of Administration: Oral
The effects on apoptosis and related signaling pathways in the t(4;14)+ multiple myeloma (MM) subset, applying drug combinations including a FGFR3 tyrosine kinase inhibitor (RTKI), the proteasome inhibitor bortezomib, and dexamethasone were tested. RTKI, bortezomib, and dexamethasone were active as single agents in t(4;14)+ MM. RTK inhibition triggered complementary proapoptotic pathways (e.g., decrease of antiapoptotic Mcl-1 protein, down-regulation of p44/42 mitogen-activated protein kinase, and activation of proapoptotic stress-activated protein/c-Jun NH(2)-terminal kinases). Synergistic or additive effects were found by combinations of RTKI with dexamethasone or bortezomib. In t(4;14)+, N-ras-mutated NCI-H929 cells, resistance to RTKI was overcome by addition of dexamethasone. Notably, the combination of RTKI and dexamethasone showed additive proapoptotic effects in bortezomib-insensitive t(4;14)+ MM.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:41:09 UTC 2023
Edited
by admin
on Wed Jul 05 22:41:09 UTC 2023
Record UNII
7S5I7G3JQL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXAMETHASONE
EMA EPAR   EP   GREEN BOOK   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
ISV-305
Code English
DEXASONE
Brand Name English
DEXAMETHASONE [MART.]
Common Name English
DEXAMETHASONE [EP MONOGRAPH]
Common Name English
DEXAMETHASONE COMPONENT OF TOBRADEX ST
Brand Name English
DEXAMETHASONE [ORANGE BOOK]
Common Name English
DEXAMETHASONE COMPONENT OF CIPRODEX
Brand Name English
DEXAMETHASONE [USP-RS]
Common Name English
LOVERINE
Brand Name English
GAMMACORTEN
Common Name English
DEXAMETASONE
Common Name English
Dexamethasone [WHO-DD]
Common Name English
MAXIDEX
Brand Name English
SUPERPREDNOL
Common Name English
DEXAMETHASONE ACETATE IMPURITY A [EP IMPURITY]
Common Name English
FORTECORTIN
Brand Name English
DEXASPORIN COMPONENT DEXAMETHASONE
Brand Name English
BETAMETHASONE IMPURITY A [EP IMPURITY]
Common Name English
DEXAMETHASONE [JAN]
Common Name English
(11.BETA.,16.ALPHA.)-9-FLUORO-11,17,21-TRIHYDROXY-16-METHYLPREGNA-1,4-DIENE-3,20-DIONE
Systematic Name English
DEXA-SINE
Brand Name English
DEXONE
Brand Name English
MAXITROL COMPONENT DEXAMETHASONE
Brand Name English
DEXAMETHASONUM [WHO-IP LATIN]
Common Name English
DEXAMETHASONE COMPONENT OF DEXASPORIN
Brand Name English
NSC-34521
Code English
DEXAMETHASONE [EMA EPAR]
Common Name English
FLUORMETHYLPREDNISOLONE
Common Name English
AEROSEB-DEX
Brand Name English
dexamethasone [INN]
Common Name English
DEXAMETHASONE COMPONENT OF DEXACIDIN
Brand Name English
DEXASITE
Brand Name English
DEXAMONOZON
Brand Name English
DEXAMETHASONE COMPONENT OF TOBRADEX
Brand Name English
DEXAMETHASONE [VANDF]
Common Name English
DEXAPOS
Brand Name English
LUXAZONE
Brand Name English
DECADRON
Brand Name English
DEXYCU
Brand Name English
TOBRADEX ST COMPONENT DEXAMETHASONE
Brand Name English
PREGNA-1,4-DIENE-3,20-DIONE, 9-FLUORO-11,17,21-TRIHYDROXY-16-METHYL-,(11.BETA.,16.ALPHA.)-9-FLUORO-11.BETA.,17,21-TRIHYDROXY-16.ALPHA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE
Common Name English
DEXACIDIN COMPONENT DEXAMETHASONE
Brand Name English
DEXAMETHASONE [WHO-IP]
Common Name English
TOBRADEX COMPONENT DEXAMETHASONE
Brand Name English
HEMADY
Brand Name English
HEXADROL
Brand Name English
DECADERM
Brand Name English
DEXAMETHASONE [USP MONOGRAPH]
Common Name English
OZURDEX
Brand Name English
ISOPTO-DEX
Brand Name English
CIPRODEX COMPONENT DEXAMETHASONE
Brand Name English
DEXAMETHASONE [HSDB]
Common Name English
DEXAMETHASONE [MI]
Common Name English
VISUMETAZONE
Common Name English
HEXADECADROL
Common Name English
DEXACORTAL
Brand Name English
9-Fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione
Systematic Name English
DECASPRAY
Brand Name English
MILLICORTEN
Common Name English
DEXACORTIN
Brand Name English
DEXAMETHASONE COMPONENT OF MAXITROL
Brand Name English
DEXTENZA
Brand Name English
16.ALPHA.-METHYL-9.ALPHA.-FLUOROPREDNISOLONE
Common Name English
APHTHASOLONE
Common Name English
OTO-104
Code English
DEXAMETHASONE [GREEN BOOK]
Common Name English
Classification Tree Code System Code
WHO-ATC R01AD03
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 8.4
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
CFR 21 CFR 522.540
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
CFR 21 CFR 520.540
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
CFR 21 CFR 520.540A
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-VATC QD10AA03
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
FDA ORPHAN DRUG 674718
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ATC S01BA01
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ATC S03BA01
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ATC D07XB05
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-VATC QR01AD03
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-VATC QD07AB19
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-VATC QH02AB02
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 17.2
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
NCI_THESAURUS C521
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
FDA ORPHAN DRUG 795620
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
NDF-RT N0000175576
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-VATC QS01CB01
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-VATC QD07XB05
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ATC C05AA09
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
CFR 21 CFR 520.540C
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ATC R01AD53
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
EMA ASSESSMENT REPORTS OZURDEX (AUTHORIZED: MACULAR EDEMA)
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-VATC QS02BA06
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
EMA ASSESSMENT REPORTS ORZUDEX (AUTHORIZED: UVEITIS)
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-VATC QD07CB04
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ATC S03CA01
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ATC S02BA06
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-VATC QS03CA01
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ATC S01CA01
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
FDA ORPHAN DRUG 626318
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-VATC QS01BA01
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
FDA ORPHAN DRUG 115298
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ATC S02CA06
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-VATC QR01AD53
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 8.3
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
LIVERTOX 288
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
CFR 21 CFR 522.542
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
NCI_THESAURUS C267
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-VATC QS03BA01
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ATC D07AB19
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-VATC QS01CA01
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-VATC QC05AA09
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
NDF-RT N0000175450
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ATC S01CB01
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
EMA ASSESSMENT REPORTS NEOFORDEX (AUTHORIZED: MULTIPLE MYELOMA)
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ATC H02AB02
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-VATC QA01AC02
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
CFR 21 CFR 520.540B
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ATC A01AC02
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ATC D10AA03
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 03
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
EU-Orphan Drug EU/3/10/763
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
CFR 21 CFR 524.1484G
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-VATC QH02BX90
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
CFR 21 CFR 520.563
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-ATC D07CB04
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
WHO-VATC QS02CA06
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
Code System Code Type Description
WIKIPEDIA
DEXAMETHASONE
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
NSC
34521
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
PUBCHEM
5743
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
NCI_THESAURUS
C422
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
DAILYMED
7S5I7G3JQL
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
LACTMED
Dexamethasone, Topical
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
HSDB
3053
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
MERCK INDEX
M4215
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY Merck Index
RXCUI
3264
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY RxNorm
DRUG BANK
DB01234
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
CHEBI
32132
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
DEXAMETHASONE
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY Description: Colourless crystals or a white or almost white, crystalline powder; odourless. Solubility: Practically insoluble in water; sparingly soluble in ethanol (~750 g/l) TS.Category: Adrenoglucocorticoid. Storage: Dexamethasone should be kept in a tightly closed container, protected from light.
CHEBI
41879
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
LACTMED
Dexamethasone
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
DRUG CENTRAL
824
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
RS_ITEM_NUM
1176007
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
FDA UNII
7S5I7G3JQL
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
MESH
D003907
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
IUPHAR
2768
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
EPA CompTox
DTXSID3020384
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
ECHA (EC/EINECS)
200-003-9
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
EVMPD
SUB07017MIG
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
CAS
50-02-2
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
ChEMBL
CHEMBL384467
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
INN
816
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
SMS_ID
100000092605
Created by admin on Wed Jul 05 22:41:09 UTC 2023 , Edited by admin on Wed Jul 05 22:41:09 UTC 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> INDUCER
TARGET -> AGONIST
BINDING
TRANSPORTER -> SUBSTRATE
METABOLIC ENZYME -> INDUCER
Related Record Type Details
METABOLITE -> PARENT
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
correction factor: for the calculation of content, multiply the peak area of impurity A by 0.75
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC